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The effect o f pam idronate treatm ent on the first developm ent o f bone m étastasés was investigated in 
124 patients with breast cancer, with either locally advanced disease (n = 33) or extraskeletal m étastasés 
(n = 91), but no bone m étastasés in  a random ised, m ulticentre, open controlled study. Patients were 
assigned to treatm ent with oral pam idronate, 300 m g/day, (n —65) or to a control group (n = 59). 
Tum our therapy was freely allowed. A  first clinical event o f  skeletal m orbidity occurred in  22% 
pam idronate and 20% control patients; unequivocal first radiological m anifestation o f bone m étastasés 
was found in 36% pam idronate and 27% control patients (n .s.). The actuarial risk o f a first skeletal 
event was sim ilar in  both groups. Quality-of-life m easurem ents o f bone m etastases-related aspects 
showed no differences between the two groups. 19 patients withdrew from the study because o f  
gastrointestinal com plaints attributed to pam idronate. We conclude that supportive oral pamidronate 
treatm ent (300 mg(day) does not prevent nor delay the developm ent of bone m étastasés in breast cancer 
patients at risk*
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INTRODUCTION
B r e a s t  c a n c e r  patients with métastasés developing first in 
extraskeletal sites (about 60% at the time of first diagnosis of 
disseminated disease) have an estimated chance of about 50% 
of developing bone métastasés [1-3]. Furthermore, patients 
presenting with locally advanced breast cancer (UICC stage 
III) have a high relapse rate; in a recent study distant métast­
asés developed in 70-80% of patients and the median relapse- 
free survival and overall survival were 2 and 4 years, respect­
ively [4], Once the disease spreads, 70% of these patients 
will eventually develop clinically manifest bone métastasés.
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Therefore, breast cancer patients with extraskeletal metastatic 
disease and patients with locally advanced disease are at 
high risk of suffering during their limited survival time, from 
impairment of their quality of life due to events of skeletal 
morbidity such as bone pain, pathological fractures and hyper- 
calcaemia. In previous studies, we and others have shown 
that long-term supportive bisphosphonate treatment reduces 
significantly skeletal morbidity in patients with breast cancer 
and established metastatic bone disease [5-8], and improves 
selective aspects of quality-of-life [9], The question arises 
whether bisphosphonate treatment, initiated in the bone met- 
astases-free stage of disease, can prevent or delay the develop­
ment of bone involvement.
In this paper, we report effects of long-term pamidronate 
treatment on the first manifestations of bone metastases. 
We assessed clinical and radiological parameters of bone
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metastases; a quality-of-life survey was also performed. This 
study was designed similarly to and conducted simultaneously 
with the earlier reported study of supportive pa mi dr on ate 
treatment of patients with breast cancer and bone metastases 
[7,9].
PATIENTS AND METHODS
Patients
This was an open, randomised study involving 124 patients 
with breast cancer and either established extraskeletal metast­
ases (n = 91), or locally advanced disease { n -  33) but no 
bone metastases at study entry. Locally advanced disease 
was defined as UICC stage Illb (TNM classification, 1987 
edition)] however, patients with a T1-3N 1-2 MO tumour 
and histologically proven positive apical axilla nodes were 
also included.
Patients were randomly assigned, per participating centre 
(9  in total), to pamidronate treatment (n = 65) or to a control 
group (n = 59). Trial participation ended with death, pamid­
ronate toxicity or on patient request. Treatment was intended 
to  be lifelong. Patients with hypercalcaemia, peptic ulcer,
*
malabsorption, creatinine clearance ^ 3 0  ml/min, and life 
expectancy ^  6 months were not included in the study. The 
study was approved by the ethical committees of the partici­
pating centres and informed verbal consent was obtained from 
all patients.
Treatment
Pamidronate was given as enteric coated tablets of 150 mg, 
to be taken with water twice daily 30 min before meals. The 
study was originally planned with a dose of 600 mg/day. In 
view o f the high incidence of gastrointestinal toxicity with this 
dose in our earlier reported study [7], the dose was reduced to 
300 mg/day. However, 6 of the 65 patients in the present 
study used 600 mg/day and these are included in the intention- 
to-treat analysis. Concomitant tumour therapy was not restric­
ted to ensure optimal treatment of changing clinical needs. 
The pamidronate tablets were prepared by the pharmacy of 
the University Hospital Leiden.
Investigations
Clinical data and blood for blood count, creatinine, alkaline 
phosphatase, calcium, phosphate, albumin and live enzymes 
were collected every 3 months. Patients were also asked to 
complete a quality-of-life questionnaire every 3 months. The 
questionnaire contained 17 items, grouped into four categor­
ies; bone pain, mobility impairment, gastrointestinal toxicity 
and fatigue. The method of the quality-of-life survey has 
been previously reported in detail [9]. The clinical data were 
collected from the patient’s files by data managers from 
regional Comprehensive Cancer Centres; the coordination of 
the data management and the quality-of-life surveys was car­
ried out by the Comprehensive Cancer Centre West, The 
Netherlands.
At entry into the study, every 6 months thereafter, and at 
any time of clinical suspicion of metastatic bone involvement, 
a bone scintigram was performed. In case of abnormalities, 
skeletal radiographs of the areas of increased isotope uptake 
were made to specify the nature of the scintigraphic findings. 
Basal bone scans and, if necessary, additional skeletal radio­
graphs were reviewed centrally to confirm the absence of bone 
metastases at the time of entry in the study. Consecutive 
investigations were reviewed for the first development of bone 
metastases by two expert readers blinded for clinical data.
Response criteria
The analysis focused only on the first manifestation of bone 
metastases. For that, clinical as well as radiological parameters 
were used. Clinically, we defined the event-free-period (EFP) 
as the time from randomisation until the first skeletal event. 
Then we calculated the actuarial risk (cumulative incidence) 
of a first skeletal event. The latter is the single or simultaneous 
occurrence of the following events of skeletal morbidity during 
a 3-month period: hypercalcaemia (serum calcium s  2.75 
mmol/I), severe bone pain requiring radiotherapy or surgery, 
(impending) pathological fracture treated with radiotherapy 
or surgery, and change of systemic therapy (chemotherapy or 
endocrine) for bone metastases as the dominant indication. In 
accordance with commonly used criteria, impending fractures 
were defined as: in long bones, osteolytic lesions greater than 
2 cm with ^ 5 0 %  cortical destruction and symptomatic with 
bone pain; in vertebrae, evident increased radionuclide uptake 
on bone scintigraphy and/or ^  50% osteolysis of vertebral 
body and arch associated with severe, localised pain. Radio- 
logically, we defined freedom-from-progress! on (FFP) as the 
time from randomisation until the first manifestation of bone 
metastases on the bone scintigraphy and/or on radiographs; 
the actuarial risk of the first radiological bone involvement was 
then calculated. If a scintigraphic abnormality preceded the 
confirmation on radiographs, the time of the first evidence on 
the bone scan determined the FFP. Overall survival is the 
period from randomisation until death while on study or until 
the end of the observation period. The quality-of-life analysis 
focused on changes over time in the scores for the four 
categories. At each follôw-up, patients scored the items on a 
4-point scale, ranging from none = 0 to very severe = 3. Then, 
for every category, the item scores were averaged.
Statistical methods
The two groups were compared by the i-test or Mann- 
Whitney test for quantitative variables and the chi-square test 
for qualitative variables. Survival curves were estimated using 
the Kaplan-Meier method and compared with the log-rank 
test. Risk factors were simultaneously tested in a multivariate 
analysis by the Cox regression model for their independent 
influence on the EFP. The sample size was calculated on the 
assumption of a 30% difference in the incidence of bone 
metastases and/or prolongation of disease-free interval by 3 
months or more (a = 0.05, p = 0.20). With 10% non-evalu- 
able patients, the study required 50 patients per arm. For the 
quality-of-life analysis, trends over time of the scores of the 
four categories evaluated were estimated using a multivariate 
repeated measurements MANOVA model [10], These esti­
mated time trends were then tested for differences between 
the two groups. Censoring, mortality and withdrawal from the 
study do not violate the assumptions underlying this method 
of analysis [9],
RESULTS
65 pamidronate and 59 control patients with comparable 
characteristics were included in the trial (Table 1).
Trial participation ended with death in 14 pamidronate and 
in 26 control patients after a median observation period o f 16 
and 20 months, respectively. The median follow-up of the 
living patients (51 pamidronate and 33 control) was 19 and 
34 months, respectively. This difference is due to early with­
drawal of 15 patients on pamidronate because of gastrointesti­
nal complaints. Consequently, the number of patients partici-
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Table 1. Patient characteristics at time of trial entry Table 2. Risk {cumulative incidence) of first events
Pamidronate Control
Number 65 59
Female/male 65/0 58/1
Median age (years)
At primary diagnosis (range) 57 (27-81) 53 (35-87)
At randomisation 61 56
Oestrogen receptor status
Positive 34 31
Negative 16 15
Unknown 15 13
Extraskeletal metastatic disease
Visceral (and soft tissue) 29 28
Soft tissue only 20 14
Locally advanced disease 16 17
Time period (months) (mean)
Primary diagnosis to first metastasis 42 33
First metastasis to randomisation 14 14
Primary diagnosis to randomisation* 1.4 1,8
Previous systemic treatment^
Chemotherapy 7 11
Endocrine therapy 14 10
Both 10 2
None 36 36
Systemic treatment at study entry
Chemotherapy 15 16
Endocrine therapy 31 20
None 19 23
* Applies only to locally advanced breast cancer patients, 1 course 
of systemic treatment before trial entry. None of the differences 
between the two groups were statistically significant.
pating in the study beyond 36 months of follow-up was too 
small for reliable group comparisons and the analysis was 
restricted to an observation period of 36 months. In addition 
to these early withdrawals, 19 pamidronate and 5 control 
patients ended trial participation on request for various 
reasons (4/19 pamidronate patients because of gastric 
intolerance)^ often after long observation periods.
Analysis of clinical parameters
14 of 65 (22%) pamidronate and 12 of 59 (20%) control 
patients developed a first skeletal event during the follow-up. 
The median time to first bone event was not reached in either 
group within the 36 months of the analysis. The presenting 
events of morbidity were two hypercalcaemic episodes, 12 
changes of systemic therapy, and one radiotherapy for bone 
pain in the pamidronate group. In the control groups the first 
clinical events of bone metastases were two hypercalcaemic 
episodes, eight changes of systemic therapy, four radiotherapy 
for bone pain, and one surgery for pathological frature. Pre­
senting events occurred simultaneously in 1 pamidronate pati­
ent compared to 3 control patients. When the actuarial risk of 
a first skeletal event was compared, no significant difference 
was found between the two groups, P=0 .57  (Table 2, 
Figure 1).
We assessed a number of risk factors for their independent 
contribution to the EFP: age ^  50 or > 50 years, locally 
advanced or extraskeletal metastatic disease, oestrogen recep­
tor status and the presence of visceral metastases. None of 
these factors was found to have a major impact on the EFP 
(P= 0.23-0.95). Overall survival was not significantly differ-
Risk of first Risk of first
clinical event radiological event
Pamidronate Control Pamidronate Control
At study start n -  65 n~59 n = 36 n = 44
At 12 months
number at risk 36 41 24 32
actuarial % 7 6 13 10
At 24 months
number at risk 17 27 7 20
actuarial % 23 22 38 29
At 3 6 months
number at risk 6 18 3 11
actuarial % 50 28 60 29
0.57 P  = 0.15
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Figure 1. Risk (cumulative incidence) of first clinical skeletal
event; P~  0.57»
ent, P =  0.30; the 3-year survival was 58% in the pamidronate 
and 55% in the control group.
Analysis of radiological parameters
At the end of the study, bone scans and skeletal radiographs 
from the four major contributing hospitals, covering 102 
(82%) of the studied patients, were reviewed centrally. On 
review, 36% of pamidronate and 27% of control patients had 
unequivocal scintigraphical and radiological evidence of first 
manifestation of bone metastases. The risk of a first radiologi­
cal manifestation of bone metastases was similar in both 
groups, P - 0 . 1 5  (Table 2, Figure 2). It is well known that
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Figure 2. Risk (cumulative incidence) of first radiological skel­
etal event: a comparison of 36 pamidronate patients and 44
control patients\ P~  0.15.
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bone scintigraphy has a high sensitivity but low specificity for 
the detection of bone metastases in breast cancer. Indeed* 
scintigraphic abnormalities were present in 30 patients at trial 
entry* but skeletal radiographs of these regions eliminated 
bone metastases in 29 patients; in one case, the presence of 
two osteolytic lesions at the time of trial entry were confirmed 
retrospectively. The patient was included in the analysis. 
W hen the analysis was restricted to the patients with a strictly 
normal bone scan at trial start, there was still no difference in 
the risk of radiological development of bone metastases (35% 
o f  pamidronate patients and 28% of control patients, 
P — 0.40).
Qua lity-of-life
Completed questionnaires were evaluable from 49 pami­
dronate and 41 control patients. At baseline, the mean scores 
o f  the two groups for the mobility impairment, bone pain 
and gastrointestinal toxicity categories were comparable, but 
pamidronate patients showed a worse score for fatigue of 0.60* 
compared to 0.30 for the control group. During follow-up* a 
significant worsening in the trend over time was found for the 
scores for mobility impairment* from 0.54 to 0.95 in the 
pamidronate and control groups alike, and gastrointestinal 
toxicity* from 0.20 to 0.45 in the pamidronate group and 
from 0,14 to 0.40 in the control group. However* for both 
categories* the worsening over time was similar in the two 
groups* P  = 0,87 and 0.88, respectively. The scores for bone 
pain and fatigue did not change significantly over time and 
there was no effect of pamidronate treatment.
DISCUSSION
Previous studies have reported extensively on the efficacy of 
bisphosphonate treatment on skeletal morbidity in patients 
with breast cancer [5-8]. In the present study* we assessed the 
ability of long-term supportive treatment with oral pamidron­
ate 300 mg/day to prevent the first manifestation of bone 
metastases in patients with an increased risk to develop meta­
static bone disease. Our results show that pamidronate in the 
dose and mode of administration used had no significant 
effect. Compared to controls, there was no evidence of a 
prevention nor of delay of the first manifestation of metastatic 
bone disease assessed both by clinical and radiological para­
meters. Also* several risk factors known to influence the pat­
tern of metastasis or prognosis were tested* but none was 
found to interact with pamidronate efficacy. Furthermore* the 
quality-of-life survey revealed comparable scores and trends 
over time for the bone metastases-related domains—bone pain 
and mobility impairment—in both pamidronate and control 
patients. This merely confirms the clinical and radiological
findings. The observed incidence of clinical events related to
i
bone metastases was lower than that of radiological changes. 
Furthermore* both were lower than expected from historical 
data; 50% in extraskeletal metastatic breast cancer and 70% 
in locally advanced disease [1-4]. These differences may be 
because* for the clinical data, we focused on the occurrence of 
severe* quality-of-life impairing skeletal events rather than on 
complaints from bone metastases because in our opinion 
the reduction of skeletal morbidity by palliative* supportive 
treatment should have major clinical impact which can be 
objectively assessed. Furthermore* less than half of the pati­
ents reached the end-point of their disease* i.e. death* during 
the observation time. A number of patients either withdrew 
from the study or participated in the study until the time of
this analysis. Obviously* bone metastases that developed after 
this time were not analysed. Last but not least, due to changing 
therapies of early breast cancer* the pattern of metastasis may 
change [11].
Previous in vivo animal studies suggested that prophylactic 
treatment with bisphosphonate clodronate in metastasis-free 
animals protects the skeleton against tumour-induced osteo­
lysis [12]. However* the present study failed to show any effect 
of pamidronate at the dose and mode of administration used 
on the first manifestation of bone metastasis. Reasons for this 
lack of an effect* which contrasts with the beneficial effect of 
pamidronate in metastatic bone disease* need to be con­
sidered. Tumour properties* such as the production of bone 
resorbing factors and interactions between invading tumour 
cells and adjacent tissues* may differ for breast cancer associ­
ated with active bone metastases compared to breast cancer 
with only extraskeletal metastases. Furthermore, there may be 
an effect of bisophosphonate dose and distribution. In the 
presence of active skeletal lesions* the bisphosphonate will 
concentrate preferentially in areas of enhanced bone resorp­
tion* i.e. the metastases. In the absence of active skeletal 
lesions* the drug will concentrate in any area of the skeleton 
undergoing remodelling* resulting in a more general distri­
bution. It may be that areas o f developing metastatic osteolysis 
are inadequately protected* perhaps even more so at lower 
doses of the bisphosphonate. This is supported by our earlier 
finding that the pamidronate efficacy to reduce skeletal mor­
bidity was dose-dependent and 300 mg/day clearly was less 
effective than 600 mg/day [7]. The negative results of the 
present study do not exclude the possibility that the bisphos­
phonate may be effective when given intravenously [13], but 
this may be difficult in a preventive setting. Alternatively* 
other newer potent bisphosphonates which can be given in 
effective doses without causing gastrointestinal toxicity may 
have a favourable effect [14].
Toxicity of treatment is of great importance when palliation 
is the objective. In 19 patients (15 early and another 4 later in 
the study) the occurrence of nausea and vomiting* and stoma­
titis in one case* was attributed to pamidronate treatment 
resulting in withdrawal from the study. In contrast to these 
clinical findings, the quality-of-life survey did not detect a 
difference in the level of gastrointestinal complaints between 
pamidronate and control patients. As reported earlier by us 
[7j 9]* primary gastrointestinal intolerance does occur, usually 
within weeks after the start of treatment. Similar complaints 
may also occur later in the course of the disease, but then they 
seem to associate more with advanced disease- and prognosis- 
related factors rather than with pamidronate treatment. The 
lack of placebo treatment in our controls carried the risk of 
attributing preferentially the gastrointestinal symptoms to the 
test drug.
In summary* in the present study* we found no beneficial 
effect of long-term pamidronate treatment at a dose of 300 
mg/day, on delaying or preventing metastatic bone involve­
ment in breast cancer patients at risk of developing bone met­
astases.
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